Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMGYXR)

Drug Name
DIZOCILPINE Drug Info
Synonyms
DIZOCILPINE; 77086-21-6; MK-801 (Dizocilpine); UNII-7PY8KH681I; MK-801; Lopac-M-108; Lopac-M-107; MK 801; Prestwick0_000109; (5S,10R)-5-methyl-10,11-dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene; 7PY8KH681I; CHEMBL284237; CHEBI:34725; Dizocilpine [INN]; Dizocilpinum [INN-Latin]; Dizocilpina [INN-Spanish]; Dizocilpinum; Dizocilpina; MK801; MK-801(Dizocilpine); HSDB 7641; (+)MK-801; (+)-MK-801; (+/-)-MK801; Prestwick2_000109; Prestwick3_000109; Prestwick1_000109; Biomol-NT_000210; SCHEMBL34528; Lopac0_000872; BSPBio_000098; SPBio_002037
Indication
Disease Entry ICD 11 Status REF
Cerebrovascular ischaemia 8B1Z Terminated [1]
Cross-matching ID
PubChem CID
180081
ChEBI ID
CHEBI:34725
CAS Number
CAS 77086-21-6
TTD Drug ID
DMMGYXR
VARIDT Drug ID
DR00506

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glycine DMIOZ29 Allergic rhinitis CA08.0 Approved [7]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [8]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [9]
SPERMINE DMD4BFY N. A. N. A. Terminated [10]
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [11]
L-698544 DMLRBN1 Alzheimer disease 8A20 Terminated [12]
RPR-104632 DM9L50N N. A. N. A. Terminated [13]
L-698532 DMO9HM7 Neurological disorder 6B60 Terminated [14]
L-695902 DMT1DNS N. A. N. A. Terminated [12]
L-701324 DMAIJSX Cerebrovascular ischaemia 8B1Z Terminated [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adenosine A3 receptor (ADORA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IB-MECA DM9G5XD Psoriasis vulgaris EA90 Phase 3 [15]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [16]
NITD609 DMQHBSX Malaria 1F40-1F45 Phase 2 [17]
CF102 DMP56WJ Hepatocellular carcinoma 2C12.02 Phase 2 [18]
SCH-442416 DMQ2K1V N. A. N. A. Phase 1 [19]
AST-004 DM5WMG7 Stroke 8B20 Phase 1 [20]
BEMESETRON DMSPJX9 N. A. N. A. Discontinued in Phase 3 [2]
BAY 60-6583 DMTEJV1 Myocardial ischemia BA6Z Preclinical [21]
CF602 DM0ULO2 Inflammation 1A00-CA43.1 Preclinical [18]
CF502 DMQSJ20 Inflammation 1A00-CA43.1 Preclinical [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Glutamate receptor ionotropic NMDA 1 (NMDAR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cycloserine DMT1I52 Bacterial infection 1A00-1C4Z Approved [22]
D-Serine DM3YH4I N. A. N. A. Phase 4 [23]
ELIPRODIL DMIOGZM Multiple sclerosis 8A40 Phase 2 [24]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [8]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [9]
SPERMINE DMD4BFY N. A. N. A. Terminated [10]
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [25]
L-698544 DMLRBN1 Alzheimer disease 8A20 Terminated [12]
RPR-104632 DM9L50N N. A. N. A. Terminated [13]
L-698532 DMO9HM7 Neurological disorder 6B60 Terminated [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha 1-PI DMXC1K9 Alpha-1 antitrypsin deficiency 5C5A Approved [26]
ELIPRODIL DMIOGZM Multiple sclerosis 8A40 Phase 2 [24]
CP-101,606 DMIU19E Parkinson disease 8A00.0 Phase 2 [27]
CERC-301 DMSABRI Major depressive disorder 6A70.3 Phase 2 [28]
RGH-896 DMCHZAN Peripheral neuropathy 8C0Z Phase 2 [29]
MIJ821 DMN45RI Major depressive disorder 6A70.3 Phase 2 [30]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [8]
Neu-2000 DMNJTLC Cardiac arrest MC82 Phase 1 [31]
EVT100 DMAKWQD Major depressive disorder 6A70.3 Phase 1 [32]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Collagen alpha-1(I) chain (COL1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [6]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [33]
Diazepam DM08E9O Alcohol withdrawal Approved [34]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [35]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [36]
Methotrexate DM2TEOL Anterior urethra cancer Approved [37]
Ceruletide DM2WE5K Caerulein stimulated gastric and pancreatic secretion 5A4Y Approved [38]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [39]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [40]
Quercetin DM3NC4M Obesity 5B81 Approved [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Catenin beta-1 (CTNNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [42]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [43]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [44]
Quercetin DM3NC4M Obesity 5B81 Approved [45]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [46]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [47]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [48]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [49]
Testosterone DM7HUNW Hot flushes GA30 Approved [50]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Glycogen synthase kinase-3 beta (GSK3B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [52]
Gefitinib DM15F0X Colon adenocarcinoma Approved [53]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [54]
Selenium DM25CGV N. A. N. A. Approved [55]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [56]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [57]
Quercetin DM3NC4M Obesity 5B81 Approved [58]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [59]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [60]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein c-Fos (FOS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [62]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [63]
Verapamil DMA7PEW Angina pectoris BA40 Approved [64]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [65]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [64]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [66]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [43]
Methotrexate DM2TEOL Anterior urethra cancer Approved [67]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [68]
Quercetin DM3NC4M Obesity 5B81 Approved [69]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Glial fibrillary acidic protein (GFAP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Penicillin V DMKVOYF Acute otitis media AB00 Approved [6]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [6]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [70]
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [71]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [72]
Testosterone DM7HUNW Hot flushes GA30 Approved [73]
Haloperidol DM96SE0 Delirium Approved [74]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [75]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [76]
Ethanol DMDRQZU Chronic pain MG30 Approved [77]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine A3 receptor (ADORA3) TTJFY5U AA3R_HUMAN Inhibitor [2]
Glutamate receptor ionotropic NMDA 1 (NMDAR1) TTLD29N NMDZ1_HUMAN Inhibitor [3]
Glutamate receptor ionotropic NMDA 2A (NMDAR2A) TTKJEMQ NMDE1_HUMAN Inhibitor [3]
Glutamate receptor ionotropic NMDA 2B (NMDAR2B) TTN9D8E NMDE2_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Gene/Protein Processing [4]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Gene/Protein Processing [5]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Drug Response [6]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Gene/Protein Processing [4]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Drug Response [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2403).
2 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
3 Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
4 Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3/-catenin signaling pathway in the SH-SY5Y cell line. Chem Biol Interact. 2019 Dec 1;314:108823. doi: 10.1016/j.cbi.2019.108823. Epub 2019 Sep 26.
5 The excitotoxity of NMDA receptor NR2D subtype mediates human fetal lung fibroblasts proliferation and collagen production. Toxicol In Vitro. 2018 Feb;46:47-57. doi: 10.1016/j.tiv.2017.10.008. Epub 2017 Oct 5.
6 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
7 Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78.
8 Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
9 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
10 Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
12 Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
13 Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
14 Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
15 A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
16 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
17 Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
18 2011 Pipeline of Can-Fite BioPharm.
19 Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
20 Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
21 Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
22 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
23 Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
24 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
26 NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
27 NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
28 Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
29 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
30 Clinical pipeline report, company report or official report of Cadent Therapeutics.
31 Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
32 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
33 Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021 Jun;109:103673. doi: 10.1016/j.jdent.2021.103673. Epub 2021 Apr 16.
34 Patterns of some extracellular matrix gene expression are similar in cells from cleft lip-palate patients and in human palatal fibroblasts exposed to diazepam in culture. Toxicology. 2009 Mar 4;257(1-2):10-6. doi: 10.1016/j.tox.2008.12.002. Epub 2008 Dec 9.
35 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
36 Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
37 Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
38 Acinar cell-specific knockout of the PTHrP gene decreases the proinflammatory and profibrotic responses in pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2014 Sep 1;307(5):G533-49. doi: 10.1152/ajpgi.00428.2013. Epub 2014 Jul 17.
39 The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. J Bone Joint Surg Am. 2001 Feb;83(2):201-11. doi: 10.2106/00004623-200102000-00007.
40 Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006 Apr;54(4):1298-308. doi: 10.1002/art.21723.
41 Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy. Invest Ophthalmol Vis Sci. 2012 Aug 31;53(9):5921-9. doi: 10.1167/iovs.12-9646.
42 Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
43 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
44 Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
45 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
46 Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
47 Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
48 Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
49 Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
50 Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
51 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
52 Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
53 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
54 The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem Biol Interact. 2019 Sep 1;310:108688. doi: 10.1016/j.cbi.2019.06.001. Epub 2019 Jun 4.
55 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
56 Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001 Sep 27;20(43):6250-7. doi: 10.1038/sj.onc.1204791.
57 Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
58 Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
59 Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact. 2010 Oct 6;188(1):75-85. doi: 10.1016/j.cbi.2010.06.001. Epub 2010 Jun 9.
60 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
61 NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity. J Biol Chem. 2021 Jan-Jun;296:100624. doi: 10.1016/j.jbc.2021.100624. Epub 2021 Apr 2.
62 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
63 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
64 Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
65 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
66 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
67 Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. 2014 Jan 20;16(1):R17. doi: 10.1186/ar4444.
68 Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation. Cardiovasc Res. 2005 Aug 1;67(2):333-41. doi: 10.1016/j.cardiores.2005.03.016. Epub 2005 Apr 21.
69 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004 Jun 25;279(26):27008-16. doi: 10.1074/jbc.M403588200. Epub 2004 Apr 16.
70 miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing. Cell Biol Toxicol. 2013 Aug;29(4):239-57. doi: 10.1007/s10565-013-9250-5. Epub 2013 Aug 1.
71 A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med. 2008 May;215(1):55-9. doi: 10.1620/tjem.215.55.
72 Aspirin-induced blockade of NF-kappaB activity restrains up-regulation of glial fibrillary acidic protein in human astroglial cells. Biochim Biophys Acta. 2006 Mar;1763(3):282-9. doi: 10.1016/j.bbamcr.2006.01.005. Epub 2006 Feb 21.
73 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
74 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
75 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
76 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
77 Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.